Cardiometabolic index and modified cardiometabolic index are associated with early neurological deterioration in patients with acute ischemic stroke - Summary - MDSpire
Advertisement
Cardiometabolic index and modified cardiometabolic index are associated with early neurological deterioration in patients with acute ischemic stroke
To assess the association of cardiometabolic index (CMI) and modified cardiometabolic index (MCMI) with early neurological decline (END) in patients with acute ischemic stroke (AIS).
Key Findings:
123 patients experienced END during hospitalization.
CMI and MCMI levels were significantly higher in the END group compared to the non-END group (p < 0.001).
Both CMI and MCMI were independent risk factors for END (all p < 0.05).
Nonlinear relationships were observed between CMI, MCMI, and END, with specific p-values indicating significance.
Interpretation:
Elevated CMI and MCMI upon admission are associated with an increased risk of early neurological decline in AIS patients, suggesting their potential use in early risk stratification and clinical decision-making.
Limitations:
Retrospective design may introduce selection bias.
Single-center study limits generalizability.
Potential confounding factors were not controlled for in the analysis.
Conclusion:
CMI and MCMI are valuable indicators for predicting early neurological decline in AIS patients, which may aid in clinical decision-making.
Tamoxifen is commonly prescribed in hormone receptor-positive breast cancer but also associated with weight gain, which can complicate survivorship care. This narrative review summarizes evidence on tamoxifen-associated weight gain and outlines pharmacologic weight management options in this population.
